305 related articles for article (PubMed ID: 17204717)
1. Integrating PET and PET/CT into the risk-adapted therapy of lymphoma.
Kasamon YL; Jones RJ; Wahl RL
J Nucl Med; 2007 Jan; 48 Suppl 1():19S-27S. PubMed ID: 17204717
[TBL] [Abstract][Full Text] [Related]
2. Monitoring cancer treatment with PET/CT: does it make a difference?
Weber WA; Figlin R
J Nucl Med; 2007 Jan; 48 Suppl 1():36S-44S. PubMed ID: 17204719
[TBL] [Abstract][Full Text] [Related]
3. Early detection of cancer recurrence: 18F-FDG PET/CT can make a difference in diagnosis and patient care.
Israel O; Kuten A
J Nucl Med; 2007 Jan; 48 Suppl 1():28S-35S. PubMed ID: 17204718
[TBL] [Abstract][Full Text] [Related]
4. PET/CT for therapy response assessment in lymphoma.
Hutchings M; Barrington SF
J Nucl Med; 2009 May; 50 Suppl 1():21S-30S. PubMed ID: 19380407
[TBL] [Abstract][Full Text] [Related]
5. FDG PET-CT in the management of primary breast lymphoma.
Santra A; Kumar R; Reddy R; Halanaik D; Kumar R; Bal CS; Malhotra A
Clin Nucl Med; 2009 Dec; 34(12):848-53. PubMed ID: 20139815
[TBL] [Abstract][Full Text] [Related]
6. PET/CT for the staging and follow-up of patients with malignancies.
Poeppel TD; Krause BJ; Heusner TA; Boy C; Bockisch A; Antoch G
Eur J Radiol; 2009 Jun; 70(3):382-92. PubMed ID: 19406595
[TBL] [Abstract][Full Text] [Related]
7. PET monitoring of therapy response in head and neck squamous cell carcinoma.
Schöder H; Fury M; Lee N; Kraus D
J Nucl Med; 2009 May; 50 Suppl 1():74S-88S. PubMed ID: 19380408
[TBL] [Abstract][Full Text] [Related]
8. 18F-FDG PET and 18F-FDG PET/CT for assessing response to therapy in esophageal cancer.
Krause BJ; Herrmann K; Wieder H; zum Büschenfelde CM
J Nucl Med; 2009 May; 50 Suppl 1():89S-96S. PubMed ID: 19380406
[TBL] [Abstract][Full Text] [Related]
9. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT.
Metser U; Even-Sapir E
Semin Nucl Med; 2007 May; 37(3):206-22. PubMed ID: 17418153
[TBL] [Abstract][Full Text] [Related]
10. Assessing tumor response to therapy.
Weber WA
J Nucl Med; 2009 May; 50 Suppl 1():1S-10S. PubMed ID: 19380403
[TBL] [Abstract][Full Text] [Related]
11. Whole-body 18F-FDG PET/CT in the presence of truncation artifacts.
Beyer T; Bockisch A; Kühl H; Martinez MJ
J Nucl Med; 2006 Jan; 47(1):91-9. PubMed ID: 16391192
[TBL] [Abstract][Full Text] [Related]
12. The role of 18F-FDG PET in assessing therapy response in cancer of the cervix and ovaries.
Schwarz JK; Grigsby PW; Dehdashti F; Delbeke D
J Nucl Med; 2009 May; 50 Suppl 1():64S-73S. PubMed ID: 19380409
[TBL] [Abstract][Full Text] [Related]
13. Impact of whole-body imaging on treatment decision to radio-frequency ablation in patients with malignant liver tumors: comparison of [18F]fluorodeoxyglucose-PET/computed tomography, PET and computed tomography.
Kuehl H; Rosenbaum-Krumme S; Veit-Haibach P; Stergar H; Forsting M; Bockisch A; Antoch G
Nucl Med Commun; 2008 Jul; 29(7):599-606. PubMed ID: 18528181
[TBL] [Abstract][Full Text] [Related]
14. Impact of FDG-PET/CT in the management of lymphoma.
Baba S; Abe K; Isoda T; Maruoka Y; Sasaki M; Honda H
Ann Nucl Med; 2011 Dec; 25(10):701-16. PubMed ID: 22037934
[TBL] [Abstract][Full Text] [Related]
15. Interpretation, accuracy and management implications of FDG PET/CT in cutaneous malignant melanoma.
Falk MS; Truitt AK; Coakley FV; Kashani-Sabet M; Hawkins RA; Franc B
Nucl Med Commun; 2007 Apr; 28(4):273-80. PubMed ID: 17325590
[TBL] [Abstract][Full Text] [Related]
16. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging in the preoperative staging of head and neck squamous cell carcinoma.
Roh JL; Yeo NK; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
Oral Oncol; 2007 Oct; 43(9):887-93. PubMed ID: 17207656
[TBL] [Abstract][Full Text] [Related]
17. The value of quantifying 18F-FDG uptake in thyroid nodules found incidentally on whole-body PET-CT.
Bogsrud TV; Karantanis D; Nathan MA; Mullan BP; Wiseman GA; Collins DA; Kasperbauer JL; Strome SE; Reading CC; Hay ID; Lowe VJ
Nucl Med Commun; 2007 May; 28(5):373-81. PubMed ID: 17414887
[TBL] [Abstract][Full Text] [Related]
18. Fever of unknown origin: the role of 18F-FDG PET/CT.
Keidar Z; Gurman-Balbir A; Gaitini D; Israel O
J Nucl Med; 2008 Dec; 49(12):1980-5. PubMed ID: 18997040
[TBL] [Abstract][Full Text] [Related]
19. FDG positron emission tomography/computed tomography scan may identify mantle cell lymphoma patients with unusually favorable outcome.
Karam M; Ata A; Irish K; Feustel PJ; Mottaghy FM; Stroobants SG; Verhoef GE; Chundru S; Douglas-Nikitin V; Oliver Wong CY; Brepoels LM
Nucl Med Commun; 2009 Oct; 30(10):770-8. PubMed ID: 19657307
[TBL] [Abstract][Full Text] [Related]
20. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma.
Park JW; Kim JH; Kim SK; Kang KW; Park KW; Choi JI; Lee WJ; Kim CM; Nam BH
J Nucl Med; 2008 Dec; 49(12):1912-21. PubMed ID: 18997056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
